Actively Recruiting
Study of Biomarkers in Gynecological Cancers
Led by University Health Network, Toronto · Updated on 2025-12-05
1000
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In recent years, there has been a significant improvement in understanding the biology of cancer and this information has been used to improve cancer care and patient outcome. Research has shown that changes in some genes and/or proteins may be important indicators for certain cancers and response to treatments. Genes are molecules made up of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). DNA contain instructions for the development and functioning of the cells in the body and are passed down from parent to child. RNA is involved with producing proteins in the body. Further research is needed to better understand the changes found in cancer cells and how to target them to stop or reduce cancer growth. A drug that may be able to block certain specific cancer cell changes is called "targeted therapy". Different people with the same type of cancer receiving the same drug could have different responses to it. For example, one person may experience a reduction of their tumor while another person's cancer may worsen. The reason for this is still not well understood and could lie in gene changes. Understanding these changes may allow researchers to predict how treatments may work in guiding decisions around choice of drugs. The purpose of the study is to learn more about gene changes or protein expression (levels) of tumors to better understand the behavior of gynecological diseases and, if possible, better address participants' cancer care now or in the future.
CONDITIONS
Official Title
Study of Biomarkers in Gynecological Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with probable or confirmed gynecological malignancy including ovarian, tubal, peritoneal, uterine, cervical, vulvar, vaginal, and rare gynecological cancers
- Age 16 years or older at time of consent
- Ability to understand and provide written informed consent
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or less
- Consent to provide tissue samples from surgery or biopsy and blood samples
- Life expectancy of at least 3 months
You will not qualify if you...
- Patients with prior neoadjuvant chemotherapy or radiation treatment for newly diagnosed gynecological cancer
- Any contraindications to tumor biopsy or blood collection procedures
- Diagnosis of high grade serous ovarian cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 1Z5
Actively Recruiting
Research Team
A
Amit Oza, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here